STOCK TITAN
  1. Home
  2. Sec-filings
  3. ICLR
  4. [6-K] ICON PLC Current Report (Foreign Issuer)

ICON plc (NASDAQ: ICLR) investors pass all AGM resolutions and back directors

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

ICON plc reported that all resolutions at its 31 July 2026 Annual General Meeting were duly passed on a vote base of 68,388,626 shares. Shareholders re-elected existing directors and elected new directors including Barry Balfe, Kevin Egan and Jeff Elliott, each receiving strong support such as 68,109,408 votes in favour for Mr. Balfe.

Shareholders also approved the review of the company’s affairs, auditor remuneration, authority to allot shares, and special resolutions disapplying statutory pre-emption rights (including for capital investment or acquisitions) and setting the price range for reissuing treasury shares. Authority for overseas market purchases of shares was renewed. ICON describes itself as a world‑leading clinical research organization with approximately 40,200 employees in 99 locations across 55 countries as of 30 June 2026.

Positive

  • None.

Negative

  • None.

Filing Explained

ICON now has approved share-action capacity, but the filing records no completed issuance, buyback, or treasury-share reissue.

Form 6-K is an interim report used by a foreign private issuer to furnish material information published in its home market. On July 31, 2026, ICON plc reported completed shareholder approval for authority to allot shares and to set aside statutory pre-emption rights, including for funding capital investment or acquisitions.

The filing does not report that any shares were allotted, so the approved authority is capacity for a possible future action rather than a completed issuance. If additional shares are issued under it, the total share count would rise and existing holders' percentage ownership would fall absent offsetting changes.

Separate approvals authorize overseas market purchases and set the price range for reissuing treasury shares; these are permissions, not reported purchases or reissues. A later company filing reporting an allotment, market purchase, or treasury-share reissue would establish whether any approved capacity has been executed.

Total votes per AGM resolution 68,388,626 votes Votes cast on each resolution at the July 31, 2026 AGM
Votes for election of Barry Balfe 68,109,408 votes For votes on Resolution 1.2 to elect Mr. Barry Balfe
Votes for Resolution 5 (pre-emption disapplication) 65,052,290 votes For votes on special Resolution 5 to disapply statutory pre-emption rights
Employees 40,200 Approximate number of employees as at June 30, 2026
Locations 99 Number of company locations worldwide as at June 30, 2026
Countries of operation 55 Number of countries where ICON operates as at June 30, 2026
statutory pre-emption rights regulatory
"To disapply the statutory pre-emption rights"
treasury shares financial
"authorise the price range at which the Company can reissue shares that it holds as treasury shares"
Treasury shares are a company’s own stock that it has repurchased and keeps on its books instead of canceling or leaving in the hands of outside investors. Think of them like coupons a business puts back in a drawer: they don’t vote or receive dividends while held, but they can be reissued later for employee pay or fundraising. For investors this matters because buybacks change the number of shares that count toward earnings and ownership, can boost per‑share metrics, and use corporate cash that might otherwise go to growth or dividends.
overseas market purchases of shares financial
"authorise the Company and any subsidiary of the Company to make overseas market purchases of shares"
forward-looking statements regulatory
"Statements included herein which are not historical facts are forward-looking statements."
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
safe harbor provisions regulatory
"Such forward-looking statements are made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995."
Safe harbor provisions are rules or legal protections that shield companies or individuals from certain penalties or liabilities when they follow specific guidelines or procedures. They provide a sense of security, encouraging compliance and innovation by reducing the fear of legal repercussions if they act in good faith. For investors, these provisions help ensure that companies are transparent and accountable without the risk of unfair punishment for honest mistakes.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 6-K: How Foreign Companies Report to the SEC →

FAQ

What did ICON plc (ICLR) announce from its July 31, 2026 AGM?
ICON plc announced that all resolutions at its July 31, 2026 Annual General Meeting were duly passed. Shareholders approved director elections, auditor remuneration, share issuance authorities, pre-emption right disapplications, treasury share pricing and overseas share repurchase authority, based on 68,388,626 votes.

Which board elections were approved at ICON plc (ICLR)'s 2026 AGM?
Shareholders re-elected several existing directors and elected Barry Balfe, Kevin Egan and Jeff Elliott to the board. For example, Barry Balfe’s election received 68,109,408 votes in favour, with relatively few votes against or withheld, indicating broad shareholder support.

What share capital authorities did ICON plc (ICLR) shareholders approve?
Shareholders authorised the company to allot shares, disapply statutory pre-emption rights (including for capital investment or acquisitions), and set the price range for reissuing treasury shares. They also renewed authority for overseas market purchases of shares by the company and its subsidiaries.

Which resolutions at ICON plc (ICLR)'s 2026 AGM were special resolutions?
Resolutions 5, 6 and 8 were designated special resolutions. They relate to disapplying statutory pre-emption rights generally, disapplying them for funding capital investment or acquisitions, and authorising the price range at which ICON can reissue shares held as treasury shares.

How many employees and locations does ICON plc (ICLR) report having?
ICON states it employed approximately 40,200 employees in 99 locations across 55 countries as at June 30, 2026. This reflects its global scale as a clinical research organization serving pharmaceutical, biotechnology, medical device, government and public health clients worldwide.

What business does ICON plc (ICLR) operate in, according to the AGM report?
ICON plc describes itself as a world-leading clinical research organization. It provides integrated consulting, clinical development, commercialization and post-marketing solutions, aiming to accelerate innovation and advance emerging therapies from molecule to medicine for global biopharma and healthcare customers.


 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 6-K
 

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of July 2026

Commission File Number: 333-08704
 
ICON plc
(Translation of registrant's name into English)
South County Business Park, Leopardstown, Dublin 18, D18 X5R3, Ireland
(Address of principal executive office)
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒   Form 40-F ☐



 



EXHIBIT LIST

ExhibitDescription
99.1
ICON Announces Results of Annual General Meeting



SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
ICON plc
Date: July 31, 2026By:/s/ Nigel Clerkin
Name:Nigel Clerkin
Title:Chief Financial Officer



Exhibit 99.1
image_0a.jpg

ICON Announces Results of Annual General Meeting

Dublin, Ireland, July 31, 2026 – ICON plc (NASDAQ: ICLR), a world-leading clinical research organization, today announced that all resolutions at the Annual General Meeting of the company (AGM) held on July 31, 2026 were duly passed by shareholders. These resolutions were set out in the Notice of the AGM sent to shareholders dated June 26, 2026 and are available on the ICON plc website.

The final results of the voting are as follows:

RESOLUTION NUMBERRESOLUTIONTOTAL NUMBER OF VOTESVOTE FORVOTE AGAINSTVOTE WITHHELD
1.1To re-elect Mr. Ciaran Murray68,388,62666,199,8692,103,46885,289
1.2To elect Mr. Barry Balfe68,388,62668,109,408193,18486,034
1.3To re-elect Mr. Rónán Murphy68,388,62667,790,940508,11089,576
1.4To re-elect Dr. John Climax68,388,62666,328,0491,971,23789,340
1.5To re-elect Ms. Julie O’Neill68,388,62667,754,504547,82386,299
1.6To re-elect Mr. Eugene McCague 68,388,62667,346,798952,21289,616
1.7To re-elect Dr. Linda Grais 68,388,62666,748,9051,553,33086,391
1.8To re-elect Ms. Anne Whitaker68,388,62668,027,624274,57986,423
1.9To elect Mr. Kevin Egan68,388,62667,829,686471,01887,922
1.10To elect Mr. Jeff Elliott68,388,62667,839,921461,02687,679
2To review the Company’s affairs and consider the Accounts and Reports68,388,62668,354,96022,86810,798
3To authorise the fixing of the Auditors' Remuneration68,388,62667,810,374570,9457,307
4To authorise the Company to allot shares68,388,62666,805,4551,577,8865,285
5**To disapply the statutory pre-emption rights 68,388,62665,052,2903,328,2528,084
6**To disapply the statutory pre-emption rights for funding capital investment or acquisitions68,388,62664,417,3163,962,7338,577
7To authorise the Company and any subsidiary of the Company to make overseas market purchases of shares68,388,62668,276,01840,50972,099

8**To authorise the price range at which the Company can reissue shares that it holds as treasury shares68,388,62668,167,370145,54875,708

** Special Resolution. All resolutions are ordinary resolutions unless otherwise stated.







About ICON plc

ICON plc is a world-leading clinical research organization. Offering deep operational and medical expertise we accelerate innovation, driving emerging therapies forward to improve patient outcomes. From molecule to medicine, we deliver integrated consulting, clinical development, commercialization and post-marketing solutions to pharmaceutical, biotechnology, medical device, government and public health organizations worldwide. With headquarters in Dublin, Ireland, ICON employed approximately 40,200 employees in 99 locations in 55 countries as at June 30, 2026. For further information about ICON, visit: www.iconplc.com.

Statements included herein which are not historical facts are forward-looking statements. Such forward-looking statements are made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Examples of forward-looking statements include, but are not limited to, statements regarding the following: contracted revenue; the repayment of indebtedness; the company's expectations regarding business momentum, market opportunity, demand trends, growth, and commercial performance; and the company's expectations with respect to its long-term value creation and competitive positioning. You can identify many forward-looking statements by words such as “aims,” “anticipates,” “believes,” “continues,” “could,” “estimates,” “expects,” “focused,” “guidance,” “intends,” “look,” “may,” “opportunities,” “plans,” “positions,” “potential,” “predicts,” “projects,” “seeks,” “should,” “will,” “would” and other similar expressions and the negatives of such expressions. However, not all forward-looking statements contain these words. These statements are based on management's current expectations and information currently available, including current economic and industry conditions. The forward looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, our results could be materially adversely affected. The risks and uncertainties include, but are not limited to, dependence on the pharmaceutical industry and certain clients, the need to regularly win projects and then to execute them efficiently and correctly, the challenges presented by rapid growth, competition and the continuing consolidation of the industry, the impact of market conditions on demand for the company's services, risks related to the company's ability to execute on its commercial strategy and maintain relationships with large pharmaceutical customers, and risks relating to the company's strategic partnerships, the dependence on certain key executives, changes in the regulatory environment, exchange rate fluctuations, inflation and rising labor costs. Please also refer to the section entitled "Risk Factors" of our Annual Report on Form 20-F for the year ended December 31, 2025 for a discussion of some of the principal risks that could adversely affect our business, operations and financial results. The company’s forward-looking statements speak only as of the date of this document or as of the date they are made, and the company undertakes no obligation to update its forward-looking statements.

Source: ICON plc
Contact: Investor Relations +1 888 381 7923
Nigel Clerkin Chief Financial Officer +353 1 291 2000
Kate Haven Vice President Investor Relations +1 888 381 7923
All at ICON
ICON/ICLR-F


Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

1 document

Press Releases